Zoetis Inc.

Manufacturer Details

There are currently no manufacturer details available.

Zoetis Inc. Drugs

Vetstarch

Vetstarch

VetStarch is administered by intravenous infusion only. The daily dose and rate of infusion depend on the patient’s blood loss, on the maintenance or restoration of hemodynamics and on the hemodilution (dilution effect). VetStarch can be administered repetitively over several days. [See Warnings and Precautions (5)] The initial 10 to 20 mL should be infused slowly, keeping the patient under close observation due to possible anaphylactoid reactions. [see General Warnings and Precautions (5.1)]

2.1 Adult Dose

As a general recommendation, the class of synthetic colloids are prescribed at doses up to 20 mL per kg of body weight per day in small animal patients.1 In a 30 kg patient, this is a dose of 600 mL of VetStarch (equivalent to 1.2 g hydroxyethyl starch and 3.1 mEq sodium per kg of body weight). The use of 6% hydroxyethyl starch 130/0.4 has been dosed at 50 mL per kg of body weight per day in human studies.2

2.2 Directions for Use of VetStarch

1. Do not remove the IV container from its overwrap until immediately before use.2. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.3. Do not administer unless the solution is clear, free from particles and the IV container is undamaged.4. VetStarch should be used immediately after insertion of the administration set.5. Do not vent.6. If administered by pressure infusion, air should be withdrawn or expelled from the bag through the medication/administration port prior to infusion.7. Discontinue the infusion if an adverse reaction occurs.8. It is recommended that administration sets be changed at least once every 24 hours.9. For single use only. Discard unused portion.

INCOMPATIBILITIES

The safety and compatibility of additives have not been established.
Ketaset

Ketaset

KETASET is well tolerated by cats and subhuman primates when administered by intramuscular injection.

Fasting prior to induction of anesthesia or restraint with KETASET is not essential; however, when preparing for elective surgery, it is advisable to withhold food for at least six hours prior to administration of KETASET.

Anesthesia may be of shorter duration in immature cats. Restraint in subhuman primate neonates (less than 24 hours of age) is difficult to achieve.

As with other anesthetic agents, the individual response to KETASET is somewhat varied depending upon the dose, general condition and age of the subject so that dosage recommendations cannot be absolutely fixed.

Dosage

Cats: A dose of 11 mg/kg (5 mg/lb) is recommended to produce restraint.

Dosages from 22 to 33 mg/kg (10 to 15 mg/lb) produce anesthesia that is suitable for diagnostic or minor surgical procedures that do not require skeletal muscle relaxation.

Subhuman Primates: The recommended restraint dosages of KETASET (ketamine hydrochloride injection, USP) for the following species are: Cercocebus torquatus (white-collared mangabey), Papio cynocephalus (yellow baboon), Pan troglodytes verus (chimpanzee), Papio anubis (olive baboon), Pongo pygmaeus (orangutan), Macaca nemestrina (pig-tailed macaque) 5 to 7.5 mg/kg; Presbytis entellus (entellus langur) 3 to 5 mg/kg; Gorilla gorilla gorilla (gorilla) 7 to 10 mg/kg; Aotus trivirgatus (night monkey) 10 to 12 mg/kg; Macaca mulatta (rhesus monkey) 5 to 10 mg/kg; Cebus capucinus (white-throated capuchin) 13 to 15 mg/kg; and Macaca fascicularis (crabeating macaque), Macaca radiata (bonnet macaque) and Saimiri sciureus (squirrel monkey) 12 to 15 mg/kg.

A single intramuscular injection produces restraint suitable for TB testing; radiography, physical examination or blood collection.

Dosage

Cats

A dose of 11 mg/kg (5 mg/lb) is recommended to produce restraint. Dosages from 22 to 33 mg/kg (10 to 15 mg/lb) produce anesthesia that is suitable for diagnostic or minor surgical procedures that do not require skeletal muscle relaxation.

Subhuman Primates

The recommended restraint dosages of KETASET for the following species are: Cercocebus torquatus (white-collared mangabey), Papio cynocephalus (yellow baboon), Pantroglodytes verus (chimpanzee), Papio anubis (olive baboon), Pongo pygmaeus (orangutan), Macaca nemestrina (pigtailed macaque) 5 to 7.5 mg/kg; Presbytis entellus (entellus langur) 3 to 5 mg/kg; Gorilla gorilla gorilla (gorilla) 7 to 10 mg/kg; Aotus trivirgatus (night monkey) 10 to 12 mg/kg; Macaca mulatta (rhesus monkey) 5 to 10 mg/kg; Cebus capucinus (white-throated capuchin) 13 to 15 mg/kg; and Macaca fascicularis (crab-eating macaque), Macaca radiata (bonnet macaque) and Saimiri sciureus (squirrel monkey) 12 to 15 mg/kg.

A single intramuscular injection produces restraint suitable for TB testing; radiography, physical examination or blood collection.

Dosage

Cats

A dose of 11 mg/kg (5 mg/lb) is recommended to produce restraint. Dosages from 22 to 33 mg/kg (10 to 15 mg/lb) produce anesthesia that is suitable for diagnostic or minor surgical procedures that do not require skeletal muscle relaxation.

Subhuman Primates

The recommended restraint dosages of KETASET for the following species are: Cercocebus torquatus (white-collared mangabey), Papio cynocephalus (yellow baboon), Pantroglodytes verus (chimpanzee), Papio anubis (olive baboon), Pongo pygmaeus (orangutan), Macaca nemestrina (pigtailed macaque) 5 to 7.5 mg/kg; Presbytis entellus (entellus langur) 3 to 5 mg/kg; Gorilla gorilla gorilla (gorilla) 7 to 10 mg/kg; Aotus trivirgatus (night monkey) 10 to 12 mg/kg; Macaca mulatta (rhesus monkey) 5 to 10 mg/kg; Cebus capucinus (white-throated capuchin) 13 to 15 mg/kg; and Macaca fascicularis (crab-eating macaque), Macaca radiata (bonnet macaque) and Saimiri sciureus (squirrel monkey) 12 to 15 mg/kg.

A single intramuscular injection produces restraint suitable for TB testing; radiography, physical examination or blood collection.
Carbocaine V Sterile Aq...

Carbocaine V Sterile Aqueous

Pharmacological studies in various species of animals, including horses, have shown that the drug produces complete and effective anesthesia at dosages that are no more than half those needed when procaine is used.

The following dosages have generally proved satisfactory in the horse and are therefore suggested as a guide:

For nerve block (diagnosis of lameness, firing, pain relief in osteoarthritis, navicular disease)— 3 to 15 mL

For epidural anesthesia (animal standing)— 5 to 20 mL

For intra-articular anesthesia (removal of fracture chips, bone and bog spavin, arthritis)— 10 to 15 mL

For infiltration (alone or in combination with nerve block or intra-articular anesthesia)— as required

For anesthesia of the laryngeal mucosa prior to ventriculectomy CARBOCAINE-V Sterile Aqueous Solution may be administered topically or by infiltration or by a combination of the two. For topical application, a total of 25 to 40 mL applied by spray (3 mL/application) is usually adequate. For infiltration, 20 to 50 mL will suffice.
Real Squeeze Aloe Vera

Real Squeeze Aloe Vera

Use 2.5 lb Aureomix® S 40/40 Granular per 1 ton (907.2 kg) of final feed. Make a preblend of 2.5 lb of Aureomix® S 40/40 Granular with part (15-20 lb) of the feed ingredients. Mix thoroughly with the remainder of the ingredients to give a final concentration of 100 g chlortetracycline and 100 g sulfamethazine per ton of feed.
Synovex C

Synovex C

Implant complete contents of one cartridge cell per calf at each implanting. 100 mg progesterone and 10 mg estradiol benzoate per implant

The twenty-dose cartridge of Synovex C is designed to be used exclusively with a Synovex SX10 Gun.

DOSAGE: One implant (four pellets), containing 100 mg of progesterone and 10 mg of estradiol benzoate, is administered to each calf by subcutaneous implantation in the middle one-third of the ear.

The twenty-dose cartridge of Synovex C is designed to be used exclusively with a Synovex SX10 Gun.

Implant complete contents of one cartridge cell per calf at each implanting. Approved implantation technique is fully described in the package insert.
Leaders Insolution Coco...

Leaders Insolution Coconut Mask With Tomato

CDS: The recommended dosage for oral administration for the control of clinical signs associated with CDS is 0.5–1.0 mg/kg once daily, preferably administered in the morning. Initially, dogs should be dosed to the nearest whole tablet. Adjustments should then be made based on response and tolerance to the drug.

PDH: The recommended dosage for the control of clinical signs associated with canine PDH is 1.0 mg/kg once daily, preferably administered in the morning. If no improvement is observed after 2 months of therapy, dosage may be increased to a maximum of 2.0 mg/kg once daily. If no improvement is seen after 1 month at the higher dose or if at any time clinical signs progress, the dog should be re-evaluated. In dogs whose clinical signs of PDH progress despite Anipryl therapy in the absence of concurrent disease, alternate therapy should be considered.

Dogs should be monitored closely for possible adverse events associated with any increase in dose.

Clinical Use of Anipryl in CDS: CDS is an age-related deterioration of cognitive abilities characterized by behavioral changes not wholly attributable to a general medical condition such as neoplasia, infection, or organ failure. CDS is typified by multiple cognitive impairments which affect the dog's function. In clinical trials, the observed behavioral changes associated with CDS in older dogs included: disorientation, decreased activity level, abnormal sleep/wake cycles, loss of housetraining, decreased or altered responsiveness to family members, and decreased or altered greeting behavior. In clinical trials, Anipryl was shown to be effective in controlling clinical signs associated with CDS. After 4 weeks of treatment, dogs treated with Anipryl showed significant improvement when compared to placebo-treated controls in sleeping patterns, house-training, and activity level. Some dogs showed increased improvement up to 3 months, however, onset, duration and magnitude of response varied with individual dogs.

The diagnosis of CDS in dogs is a diagnosis of exclusion, based on thorough behavioral and medical histories, in conjunction with appropriate diagnostic work-up and testing.11 Periodic patient monitoring to evaluate the response and tolerance to the drug and for the presence of concurrent or new disease is recommended.

Clinical Use of Anipryl in PDH: Clinical signs of PDH seen in clinical trials included panting, reduced activity, polydipsia, polyuria, changes in sleep patterns, altered appetite, obesity, alopecia, abdominal distention, reduced skin elasticity, thin skin, poor hair growth, pyoderma, decreased responsiveness to attention, and decreased enthusiasm of greeting. In clinical studies involving 125 evaluable cases of naturally occurring PDH, Anipryl was shown to be effective in controlling clinical signs associated with the disease. On physical examination, abdominal distention was the parameter which most consistently improved following treatment with Anipryl. Based on owner assessments, activity level was the parameter most consistently evaluated as "improved." Approximately 60% of the dogs were evaluated by the veterinarians and owners to be "slightly improved" to "improved" after 1 month of Anipryl therapy. By month 2, veterinarians reported that approximately 77% were "slightly improved" to "improved." Approximately 20% of dogs did not respond to Anipryl and were deemed treatment failures.

Those dogs that responded to Anipryl tended to do so within 1–2 months after treatment was initiated. Response to therapy varied between patients with some dogs showing improvement in all presenting clinical signs and others showing improvement in only 1–2 parameters. Duration of response was also variable, with some dogs continuing on Anipryl for over 1 year with good control of clinical signs and others showing an initial response to therapy only to be followed within several months by recurrence of clinical signs of PDH. There was no correlation demonstrated between an individual dog's clinical response to Anipryl and that dog's low dose dexamethasone suppression test results, therefore, monitoring should be based on history and physical examination findings.

SAFETY: In a laboratory safety study, Anipryl was administered orally to healthy adult beagles once daily for 6 months at doses of 0, 1, 2, 3, or 6 mg/kg (0.5×, 1×, 1.5× and 3× the maximum recommended daily dose of 2.0 mg/kg). The drug was demonstrated to be safe at the recommended dose range of 0.5–2.0 mg/kg. The following statistically significant clinical observations were noted in dogs in the 1.5× and 3× group: salivation, decreased pupillary response, and decreased body weight despite normal to increased feed consumption. Additional reactions seen at the 3× dose included panting, decreased skin elasticity (dehydration) and stereotypic behaviors, i.e., weaving (repetitive left to right movement) in the cage. This repetitive movement started several hours after dosing but was no longer present at the time of the next morning dose. There were no changes noted in blood pressure, heart rate and ECG parameters, nor were there any ophthalmic changes.
Draxxin

Draxxin

Cattle

Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.
Table 1. DRAXXIN Cattle Dosing Guide Animal Weight(Pounds) Dose Volume(mL) 100 1.1 200 2.3 300 3.4 400 4.5 500 5.7 600 6.8 700 8.0 800 9.1 900 10.2 1000 11.4
Swine

Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.
Table 2. DRAXXIN Swine Dosing Guide Animal Weight(Pounds) Dose Volume(mL) 15 0.2 30 0.3 50 0.6 70 0.8 90 1.0 110 1.3 130 1.5 150 1.7 170 1.9 190 2.2 210 2.4 230 2.6 250 2.8 270 3.1 290 3.3
Sapphire 30 Special Ord...

Sapphire 30 Special Order

DOSAGE AND ADMINISTRATION: ANTISEDAN is administered intramuscularly (IM) for reversal of sedation and analgesia regardless of the route used for DEXDOMITOR or DOMITOR. The atipamezole dose for the reversal of IV DEXDOMITOR or DOMITOR is 3750 mcg/m2. The atipamezole dose for the reversal of IM DEXDOMITOR or DOMITOR is 5000 mcg/m2.

The dosage of ANTISEDAN is calculated based on body surface area. Use the following tables to determine the correct injection volume or the correct ANTISEDAN dosage on the basis of kilograms of body weight.

Note that the mcg/kg dosage decreases as body weight increases.
Table 1: Atipamezole dosing for reversal of IV dexmedetomidine- or medetomidine-induced sedation/analgesia: Dose table for ANTISEDAN (3750 mcg/m2) when dexmedetomidine or medetomidine is given IV For # lbs For # kg dose = mcg/kg volume = mL ANTISEDAN 4-7 2-3 300 0.1 7-9 3-4 250 0.15 9-11 4-5 230 0.2 11-22 5-10 200 0.3 22-33 10-15 170 0.4 33-44 15-20 150 0.5 44-55 20-25 140 0.6 55-66 25-30 130 0.7 66-81 30-37 120 0.8 81-99 37-45 110 0.9 99-110 45-50 105 1.0 110-132 50-60 100 1.1 132-143 60-65 95 1.2 143-165 65-75 93 1.3 165-176 75-80 91 1.4 >176 >80 90 1.5 Table 2: Atipamezole dosing for reversal of IM dexmedetomidine- or medetomidine-induced sedation/analgesia: Dose table for ANTISEDAN (5000 mcg/m2) when dexmedetomidine or medetomidine is given IM For # lbs For # kg dose = mcg/kg volume = mL ANTISEDAN 4-7 2-3 400 0.15 7-9 3-4 350 0.2 9-11 4-5 300 0.3 11-22 5-10 250 0.4 22-29 10-13 230 0.5 29-33 13-15 210 0.6 33-44 15-20 200 0.7 44-55 20-25 180 0.8 55-66 25-30 170 0.9 66-73 30-33 160 1.0 73-81 33-37 150 1.1 81-99 37-45 145 1.2 99-110 45-50 140 1.3 110-121 50-55 135 1.4 121-132 55-60 130 1.5 132-143 60-65 128 1.6 143-154 65-70 125 1.7 154-176 70-80 123 1.8 >176 >80 120 1.9
Antirobe Aquadrops

Antirobe Aquadrops

Dogs:

Infected Wounds, Abscesses, and Dental Infections

Oral: 2.5-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with ANTIROBE products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.

Dosage Schedule:

Capsules

ANTIROBE 25 mg, administer 1-6 capsules every 12 hours for each 10 pounds of body weight.

ANTIROBE 75 mg, administer 1-6 capsules every 12 hours for each 30 pounds of body weight.

ANTIROBE 150 mg, administer 1-6 capsules every 12 hours for each 60 pounds of body weight.

Liquid

ANTIROBE AQUADROPS, administer 1-6 mL/10 lbs body weight every 12 hours.

Dogs:

Osteomyelitis

Oral: 5.0-15.0 mg/lb body weight every 12 hours

Duration: Treatment with ANTIROBE is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.

Dosage Schedule:

Capsules

ANTIROBE 25 mg, administer 2-6 capsules every 12 hours for each 10 pounds of body weight.

ANTIROBE 75 mg, administer 2-6 capsules every 12 hours for each 30 pounds of body weight.

ANTIROBE 150 mg, administer 2-6 capsules every 12 hours for each 60 pounds of body weight.

Liquid

ANTIROBE AQUADROPS, administer 2-6 mL/10 lbs body weight every 12 hours.

Cats:

Infected Wounds, Abscesses, and Dental Infections

5.0 - 15.0 mg/lb body weight once every 24 hours depending on the severity of the condition.

Duration: Treatment with ANTIROBE AQUADROPS Liquid may be continued up to a maximum of 14 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three to four days if no clinical response to therapy is seen.

Dosage Schedule:

ANTIROBE AQUADROPS, to provide 5.0 mg/lb, administer 1 mL/5 lbs body weight once every 24 hours; to provide 15.0 mg/lb, administer 3 mL/5 lbs body weight once every 24 hours.
Celecoxib

Celecoxib

DOSAGE AND ADMINISTRATION: Always provide Client Information Sheet with prescription. Carefully consider the potential benefits and risk of Rimadyl and other treatment options before deciding to use Rimadyl. Use the lowest effective dose for the shortest duration consistent with individual response. The recommended dosage for oral administration to dogs is 2 mg/lb (4.4 mg/kg) of body weight daily. The total daily dose may be administered as 2 mg/lb of body weight once daily or divided and administered as 1 mg/lb (2.2 mg/kg) twice daily. For the control of postoperative pain, administer approximately 2 hours before the procedure. Caplets are scored and dosage should be calculated in half-caplet increments.
Agaricus E Pl. Tota 6 S...

Agaricus E Pl. Tota 6 Special Order

DOSAGE: One implant containing 40 mg of trenbolone acetate and 8 mg of estradiol is administered to each animal. The 2 pellets that make up the dosage of Synovex T40 are contained in one division of the multiple dose cartridge. The ten-dose cartridge of Synovex T40 is designed to be used exclusively with a Synovex SX10 gun.
Spectramast Dc

Spectramast Dc

Infuse one (1) syringe into each affected quarter at the time of dry off.

DIRECTIONS FOR USING THE PLASTET® DISPOSABLE SYRINGE

The syringe is designed to provide the choice of either insertion of the full cannula as has traditionally been practiced, or insertion of no more than 1/8 inch of the cannula, as reported by Eberhart, R.J., et. al. 1987. Current Concepts of Bovine Mastitis, 3rd Edition, National Mastitis Council, Arlington, VA.
a. Full insertion: Remove the red end cap by pulling straight up as shown. Gently insert the full cannula into the teat canal; carefully infuse the product. b. Partial insertion: Remove the red end cap by pulling straight up as shown. Gently insert the exposed white tip into the teat canal; carefully infuse the product.
ADMINISTRATION

Treatment: Wash teats thoroughly with warm water containing a suitable dairy antiseptic. Dry teats thoroughly. Milk out udder completely. Using an alcohol pad provided, wipe off the end of the affected teat using a separate pad for each teat. Choose the desired insertion length (full or partial) and insert tip into teat canal; push plunger to dispense entire contents, massage the quarter to distribute the suspension into the milk cistern.

Reinfection: After successful treatment, reinfection may occur unless good herd management, sanitation, and mechanical safety measures are practiced. Affected cows should be watched carefully to detect recurrence of infection and possible spread to other animals.
Albon

Albon

Initial Dose: 25 mg/lb (55 mg/kg) of animal body weight.

Subsequent Daily Doses: 12.5 mg/lb (27.5 mg/kg) of animal body weight.

Dogs and cats should receive 1 teaspoonful of Albon Oral Suspension 5% per 10 lb of body weight (25 mg/lb or 55 mg/kg) as an initial dose, followed by 1/2 teaspoonful per 10 lb of body weight (12.5 mg/lb or 27.5 mg/kg) every 24 hours thereafter. Representative weights and doses are indicated in the following table:
Animal Weight Initial Dose25 mg/lb(55 mg/kg) Subsequent Daily Doses12.5 mg/lb(27.5 mg/kg) 5 lb (2.2 kg) 1/2 tsp (2 1/2 mL) 1/4 tsp (1 1/4 mL) 10 lb (4.5 kg) 1 tsp (5 mL) 1/2 tsp (2 1/2 mL) 20 lb (9.1 kg) 2 tsp (10 mL) 1 tsp (5 mL) 40 lb (18.2 kg) 4 tsp (20 mL) 2 tsp (10 mL) 80 lb (36.4 kg) 8 tsp (40 mL) 4 tsp (20 mL)
Treatment may be initiated with Albon Injection 40% to obtain effective blood levels almost immediately or to facilitate treatment of the fractious animal.

Length of treatment depends on the clinical response. In most cases treatment for 3–5 days is adequate. Treatment should be continued until the animal is asymptomatic for 48 hours.
Slentrol

Slentrol

DOSAGE AND ADMINISTRATION: SLENTROL should be prescribed as part of an overall weight management program that incorporates a complete and balanced canine diet and physical activity.

Dietary Considerations: SLENTROL should only be used with a commercial maintenance diet. Any diet changes should be made gradually and prior to initiating SLENTROL treatment. Better appetite control may be achieved in diets that are not restricted in fat content. Changing the diet while initiating treatment with SLENTROL should be avoided.

The dog will need to be weighed at the start of treatment and then at monthly intervals so that the dosing regimen can be adjusted according to the prescribing instructions below.

During the first month of therapy, the dosing regimen for SLENTROL consists of two fixed dose rates (number of mL administered per unit of body weight) in all dogs. In subsequent months of therapy, the recommended dosing regimen prescribed for SLENTROL varies for each individual dog and the dose volume must be specifically calculated each month, based on the amount of weight lost (expressed as a percent) during the previous month of therapy.

With regard to dosing it is important to note that:
Initial body weight is used to calculate the dose that is first administered. Subsequent dose adjustments are made by adjusting the volume of solution administered. Dose adjustments are determined at monthly intervals. A diet change at the time of a dose escalation should be avoided.
The dose should not exceed a maximum daily dose of 0.2 mL/kg (0.09 mL/lb), based on the dog's current body weight, during any part of treatment.

Dose Preparation and Administration: To prepare for oral administration, remove the bottle cap and insert the supplied oral dosing syringe through the membrane into the bottle. Invert the bottle and withdraw the appropriate volume required using the graduation marks on the side of the oral dosing syringe.

The 1 mL dosing syringe provided with SLENTROL can not accurately measure the dosage required to treat dogs that weigh less than 12.5 lb (5.7 kg).

A veterinarian or veterinary technician should instruct the pet owner/caregiver on how to measure the amount of SLENTROL to be administered to ensure accurate dosing.

SLENTROL can be administered directly into the dog's mouth or on a small amount of food. It can be given with a meal or at a different time of day.

Wipe the oral dosing syringe clean after each use with a clean dry cloth or disposable towel. Do not introduce water into the oral dosing syringe or the SLENTROL solution.
Lincocin Aquadrops

Lincocin Aquadrops

Oral: 10 mg per pound of body weight every 12 hours or 7 mg per pound every 8 hours.

Intramuscular: 10 mg per pound of body weight once a day or 5 mg per pound every 12 hours.

Intravenous: 5 to 10 mg per pound of body weight one or two times per day diluted with 5 percent glucose in water or normal saline and given as a drip infusion.

Treatment with LINCOCIN products may be continued for periods as long as 12 days if clinical judgment indicates.

As with any multi-dose vial, practice aseptic techniques in withdrawing each dose. Adequately clean and disinfect the vial closure prior to entry with a sterile needle and syringe.
Palladia

Palladia

Always provide Client Information Sheet with prescription. Administer an initial dosage of 3.25 mg/kg (1.48 mg/lb) body weight, orally every other day (see Table 1). Dose reductions of 0.5 mg/kg (to a minimum dose of 2.2 mg/kg (1.0 mg/lb) every other day) and dose interruptions (cessation of PALLADIA for up to two weeks) may be utilized, if needed, to manage adverse reactions (see Table 2 as well as Warnings and Precautions). Adjust dose based on approximately weekly veterinary assessments for the first 6 weeks and approximately every 6 weeks, thereafter. PALLADIA may be administered with or without food. Do not split tablets.
Table 1. 3.25 mg/kg Dose Chart Dog Body Weight Number of Tablets Pounds Kilograms Dose 10 mg 15 mg 50 mg 11.0 – 11.8 5.0 - 5.3 15 mg 1 11.9 – 15.2 5.4 - 6.9 20 mg 2 15.3 – 18.5 7.0 - 8.4 25 mg 1 1 18.6 – 22.0 8.5 - 10.0 30 mg 2 22.1 – 25.4 10.1 - 11.5 35 mg 2 1 25.5 – 28.7 11.6 - 13.0 40 mg 1 2 28.8 – 32.2 13.1 - 14.6 45 mg 3 32.3 – 35.5 14.7 - 16.1 50 mg 1 35.6 – 38.8 16.2 - 17.6 55 mg 1 3 38.9 – 42.3 17.7 - 19.2 60 mg 1 1 42.4 – 45.6 19.3 - 20.7 65 mg 1 1 45.7 – 50.7 20.8 - 23.0 70 mg 2 1 50.8 – 59.3 23.1 - 26.9 80 mg 2 1 59.4 – 65.9 27.0 - 29.9 95 mg 3 1 66.0 – 71.2 30.0 - 32.3 100 mg 2 71.3 – 76.3 32.4 - 34.6 110 mg 1 2 76.4 – 79.6 34.7 - 36.1 115 mg 1 2 79.7 – 84.7 36.2 - 38.4 120 mg 2 2 84.8 – 94.8 38.5 - 43.0 130 mg 2 2 94.9 – 105.0 43.1 - 47.6 150 mg 3 105.1 – 110.0 47.7 - 49.9 160 mg 1 3 110.1 – 113.5 50.0 - 51.5 165 mg 1 3 113.6 – 118.6 51.6 - 53.8 170 mg 2 3 118.7 – 128.8 53.9 - 58.4 180 mg 2 3 128.9 – 138.9 58.5 - 63.0 200 mg 4 139.0 – 144.0 63.1 - 65.3 210 mg 1 4 144.1 – 157.6 65.4 - 71.5 215 mg 1 4 157.7 – 173.1 71.6 - 78.5 250 mg 5 173.2 – 177.9 78.6 - 80.7 260 mg 1 5 178.0 – 191.6 80.8 - 86.9 265 mg 1 5 191.7 – 220.5 87.0 - 100.0 300 mg 6 Table 2. Dose Modification Based on Toxicity Observed Toxicity Dose Adjustment Neutropenia >1000/µL Maintain dose level ≤1000/µL or neutropenic fever or infection Stop drug until >1000/µL and clinical signs normal; then decrease dose by 0.5 mg/kg Renal Toxicities (Creatinine) <2.0 mg/dL Maintain dose level ≥2.0 mg/dL Stop drug until <2.0 mg/dL then decrease dose by 0.5 mg/kg Albumin <1.5 g/dL Stop drug until >2.5 g/dL then decrease dose by 0.5 mg/kg Hematocrit <26% Stop drug until >30% then decrease dose by 0.5 mg/kg Diarrhea <4 watery stools/day for less than 2 days Maintain dose level and institute supportive care ≥4 watery stools/day or ≥ 2 days Stop drug until formed stools and institute supportive care. When dosing is resumed, decrease dose by 0.5 mg/kg GI Bleeding Fresh blood in stool or black tarry stool for > 2 days or frank hemorrhage or blood clots in stool. Stop drug and institute supportive care until resolution of all clinical signs of blood in stool, then decrease dose by 0.5 mg/kg.
Tucoprim

Tucoprim

The recommended dose is 3.75 grams TUCOPRIM Powder per 50 kg (110 lbs) body weight per day. Each level, loose-filled scoop contains approximately 15 grams which is sufficient to treat 200 kg (440 lbs) of body weight. Since product contents may settle, gentle agitation during scooping is recommended. Administer orally once a day in a small amount of palatable feed.

The usual course of treatment is a single, daily dose for five to seven days. Continue acute infection therapy for two or three days after clinical signs have subsided. If no improvement of acute infections is seen in three to five days, re-evaluate diagnosis.

Trimethoprim/sulfadiazine may be used alone or in conjunction with intravenous dosing. Following treatment with trimethoprim/sulfadiazine 48% Injection, therapy can be maintained using oral powder.

A complete blood count should be done periodically in patients receiving trimethoprim/sulfadiazine for prolonged periods. If significant reduction in the count of any formed blood element is noted, treatment with trimethoprim/sulfadiazine should be discontinued.
Strongid

Strongid

Strongid Paste is to be administered as a single oral dose of 3 mg pyrantel base per lb of body weight. The syringe has 4 weight mark increments. Each weight mark indicates the recommended dose for 300 lb of body weight.
Dosage Body Weight Range Volume mg Pyrantel Base up to 300 lb 1/4 syringe (5 mL) 900 mg 301–600 lb 1/2 syringe (10 mL) 1800 mg 601–900 lb 3/4 syringe (15 mL) 2700 mg 901–1200 lb 1 full syringe (20 mL) 3600 mg
Note: Position screw-gauge over appropriate mark on plunger. Each mL contains 180 mg of pyrantel base as pyrantel pamoate.

For maximum control of parasitism, it is recommended that foals (2–8 months of age) be dosed every 4 weeks. To minimize the potential source of infection that the mare may pose to the foal, the mare should be treated 1 month prior to anticipated foaling date followed by retreatment 10 days to 2 weeks after birth of foal. Horses and ponies over 8 months of age should be routinely dosed every 6 weeks.

After removing the cap, the paste should be deposited on the dorsum of the tongue. Introduce the nozzle end of the syringe at the corner of the mouth. Direct the syringe backwards and depress the plunger to deposit the paste onto the tongue. Given in this manner, it is unlikely that rejection of the paste will occur. Raising the horse's head sometimes assists in the swallowing process. When only part of the paste has been used, replace the cap on the syringe nozzle.
Albadry Plus

Albadry Plus

Infuse one tube per quarter at start of dry period (but not less than 30 days prior to calving).

Shake Well Before Using

The FLEXI-TUBE is designed to provide the choice of either insertion of the full cannula, as has traditionally been practiced, or insertion of no more than ⅛ inch of the cannula, as recommended by the National Mastitis Council.
a. Full Insertion: Remove the blue end cap by pulling straight up as shown. Gently insert the full cannula into the teat canal; carefully infuse the product. a. b. Partial Insertion: Remove both the blue end cap and the red cannula by pushing sideways as shown. Gently insert the exposed blue tip into the teat canal; carefully infuse the product. b.
At the time of drying off, but not less than 30 days prior to calving, milk the udder dry. Wash the teats and udder thoroughly with warm water containing a suitable dairy antiseptic. Dry the teats and udder thoroughly. Infuse each quarter using the following procedure. Using the alcohol pads provided, scrub each teat end clean using a separate pad for each teat. Warm ALBADRY PLUS Suspension to body temperature and shake thoroughly. Choose the desired insertion length (full or partial) and insert tip into teat canal. Instill entire contents into the quarter. Massage the udder after treatment to distribute the ALBADRY PLUS Suspension throughout the quarters. Using a suitable teat dip, dip all teats following treatment.
Temaril-p

Temaril-p

The same dosage schedule may be followed for both antipruritic and antitussive therapy.
Weight of Dog Initial Dosage Up to 10 lb 1/2 tablet, twice daily 11–20 lb 1 tablet, twice daily 21–40 lb 2 tablets, twice daily Over 40 lb 3 tablets, twice daily
After 4 days, reduce dosage to 1/2 of the initial dose or to an amount just sufficient to maintain remission of symptoms. Individual animal response will vary and dosage should be adjusted until proper response is obtained.
Zeniquin

Zeniquin

DOSAGE AND ADMINISTRATION: The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb.

For the treatment of skin and soft tissue infections, Zeniquin tablets should be given for 2–3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Zeniquin tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Drug Interactions: Compounds (e.g., sucralfate, antacids, and mineral supplements) containing divalent and trivalent cations (e.g., iron, aluminum, calcium, magnesium, and zinc) can interfere with the absorption of quinolones which may result in a decrease in product bioavailability. Therefore, the concomitant oral administration of quinolones with foods, supplements, or other preparations containing these compounds should be avoided.
Zoamix

Zoamix

It is suggested that a mixture of Zoamix and some feed ingredient be prepared prior to mixing in with the finished ration. This will ensure thorough and even distribution in the feed.

For chickens grown for meat purposes:

Use 1 lb (454 g) of Zoamix per 2,000 lb (909 kg) of finished product to produce a feed containing 0.0125% zoalene. Zoamix should be thoroughly blended into the finished feed. Feed containing zoalene should be fed continuously as the only ration from the time chicks are placed in floor pens until they are slaughtered for meat.

For replacement chickens:

Feed containing zoalene can be used in a program to raise replacement birds. When used under conditions of exposure to coccidiosis, it will allow immunity to develop adequate to protect against losses due to the disease when the birds are placed on nonmedicated feed for egg laying purposes. The following chart outlines the type of feeding program to follow where complete formulated feed is the sole ration:
Starter ration Grower ration* Growing condition % Zoalene per ton Zoamix to be added per ton of feed % Zoalene in feed Zoamix to be added per ton of feed (lb) (g) (lb) (g) * Grower ration not to be fed to birds over 14 weeks of age. Severe exposure to coccidiosis expected 0.0125 1 454 0.0083 to 0.0125 2/3 to 1 303 to 454 Light to moderate exposure to coccidiosis expected 0.0083 to 0.0125 2/3 to 1 303 to 454 0.004 to 0.0083 1/3 to 2/3 151 to 303
For turkeys grown for meat purposes only:

When turkey poults are reared in confinement and severe exposure to coccidiosis is usually a problem, use 1½ lb (681 g) of Zoamix per ton (2,000 lb) of feed to produce a finished feed containing 0.0187% zoalene. Under the usual conditions of rearing turkey poults, or when turkey poults are on range, use 1 lb (454 g) of Zoamix per 2,000 lbs (909 kg) of feed to produce a finished feed containing 0.0125% zoalene. The feed containing zoalene should be fed continuously until the birds are 14 to 16 weeks of age.
Dectomax Pour-on

Dectomax Pour-on

There is currently no dosage information available for this product. We apologize for any inconvenience.
Terramycin

Terramycin

Terramycin Ophthalmic Ointment with Polymyxin B Sulfate should be administered topically to the eye 2–4 times daily.
Re-sorb

Re-sorb

Mixing Directions: Add the contents of 1 packet (both sides) to 2 quarts of warm water. Stir until dissolved.

Scouring Calves: Feed 2 quarts of Re-Sorb solution made up as directed, twice daily for 2 days (4 feedings). No milk or milk replacer should be fed during this period. For the next 4 feedings (days 3 and 4), use 1 quart of Re-Sorb solution mixed together with 1 quart of milk or milk replacer. Thereafter, feed as normal.

Newly Purchased Calves: Feed 2 quarts of Re-Sorb solution made up as directed instead of milk as the first feed upon arrival. For the next scheduled feeding, use 1 quart of Re-Sorb solution mixed together with 1 quart of milk or milk replacer. Thereafter, feed as normal.
Apoquel

Apoquel

Dosage and Administration: The dose of APOQUEL (oclacitinib maleate) tablets is 0.18 to 0.27 mg oclacitinib/lb (0.4 to 0.6 mg oclacitinib/kg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy. APOQUEL may be administered with or without food.
Dosing Chart Weight Range(in lb) Weight Range(in Kg) Number of Tablets to be Administered Low High Low High 3.6 mg Tablets 5.4 mg Tablets 16 mg Tablets 6.6 9.9 3.0 4.4 0.5 - - 10.0 14.9 4.5 5.9 - 0.5 - 15.0 19.9 6.0 8.9 1 - - 20.0 29.9 9.0 13.4 - 1 - 30.0 44.9 13.5 19.9 - - 0.5 45.0 59.9 20.0 26.9 - 2 - 60.0 89.9 27.0 39.9 - - 1 90.0 129.9 40.0 54.9 - - 1.5 130.0 175.9 55.0 80.0 - - 2
Pirsue

Pirsue

Infuse one (1) syringe into each affected quarter. Use proper teat end preparation and sanitation and proper intramammary infusion technique (see ADMINISTRATION). Repeat treatment after 24 hours. Daily treatment may be repeated at 24-hour intervals for up to 8 consecutive days.

Teat End Preparation: Wash teats thoroughly with water containing a suitable dairy antiseptic. Dry the teats thoroughly. Milk out the udder completely. Using the alcohol pad provided, wipe the teat end of the affected quarters, using a separate pad for each teat. Allow sufficient time (at least 5 to 10 seconds) for the alcohol to dry. Use of protective gloves by persons applying treatment is recommended as part of aseptic infusion technique.

Important Considerations for Extended Therapy: For extended duration of therapy, infuse only quarters known to be infected with label pathogens. Do not concurrently infuse uninfected low SCC quarters of the same cow. Prepare the teats using the above instructions, and then infuse PIRSUE Sterile Solution using aseptic infusion technique and partial insertion (see diagram below).

Infusion: The Plastet disposable syringe is designed to provide the choice of either insertion of the full cannula as has traditionally been practiced, or insertion of no more than 1/8 inch of the cannula, as reported by Eberhart, R.J., et. al., 1987. Current Concepts of Bovine Mastitis, 3rd Edition, National Mastitis Council, Arlington, VA.

a. Full insertion: Remove the white end cap by pulling straight up as shown. Gently insert the full cannula into the teat canal.

b. Partial insertion: Remove the white end cap by pulling straight up as shown. Gently insert the exposed white tip into the teat canal.

Choose the desired insertion length (full or partial) and gently insert the tip into the teat canal. Carefully push the plunger to infuse the entire contents, and then massage the quarter to distribute the solution into the milk cistern. Following infusion, dip all quarters with an antiseptic teat dip. Cows with systemic clinical signs caused by mastitis should receive other appropriate therapy under the direction of a licensed veterinarian.

Reinfection: After treatment, reinfection may occur unless good herd management, sanitation, and mechanical safety measures are practiced. Affected cows should be watched carefully to detect recurrence and possible spread of infection to other animals.
Cestex

Cestex

DOSAGE AND ADMINISTRATION: Cestex tablets should be administered orally.

The recommended dosage of epsiprantel is: cats, 1.25 mg/lb of body weight; dogs, 2.5 mg/lb of body weight. The following table may be used as a guide:
Dosage Schedule Feline Body Weight Dose Seven weeks old up to 10 lb 12.5 mg 11–20 lb 25.0 mg Canine Body Weight Dose Seven weeks old up to 5 lb 12.5 mg 6–10 lb 25.0 mg 11–20 lb 50.0 mg 21–40 lb 100.0 mg 41–50 lb 125.0 mg 51–60 lb 150.0 mg 61–80 lb 200.0 mg 81–90 lb 225.0 mg 91–100 lb 250.0 mg 101+ lb 2.5 mg/lb, rounding up to next whole tablet combination
Fasting is not necessary or recommended.

Unless exposure to the infected intermediate hosts is controlled, reinfection is likely and retreatment may be required. In the case of D. caninum, an effective flea control program should be instituted.
Depo-medrol

Depo-medrol

INTRAMUSCULAR

Following intramuscular injection of methylprednisolone acetate, a prolonged systemic effect results. The dose varies with the size of the animal patient, the severity of the condition under treatment, and the animal's response to therapy.

Dogs and Cats. The average intramuscular dose for dogs is 20 mg. In accordance with the size of the dog and severity of the condition under treatment, the dose may range from 2 mg in miniature breeds to 40 mg in medium breeds, and even as high as 120 mg in extremely large breeds or dogs with severe involvement.

The average intramuscular dose for cats is 10 mg with a range up to 20 mg.

Injections may be made at weekly intervals or in accordance with the severity of the condition and clinical response.

Horses. The usual intramuscular dose for horses is 200 mg repeated as necessary. For maintenance therapy in chronic conditions, initial doses should be reduced gradually until the smallest effective (ie, individualized) dose is established. MEDROL® Tablets containing methylprednisolone may also be used for maintenance in dogs and cats, administered according to the recommended dose.

When treatment is to be withdrawn after prolonged and intensive therapy, the dose should be reduced gradually.

If signs of stress are associated with the condition being treated, the dose should be increased. If a rapid hormonal effect of maximum intensity is required, as in anaphylactic shock, the intravenous administration of highly soluble SOLU-DELTA-CORTEF® Sterile Powder containing prednisolone sodium succinate is indicated.

INTRASYNOVIAL

Methylprednisolone acetate, a slightly soluble ester of methylprednisolone, is capable of producing a more prolonged local anti-inflammatory effect than equimolar doses of hydrocortisone acetate. Following intrasynovial injection, relief from pain may be experienced within 12 to 24 hours. The duration of relief varies, but averages three to four weeks, with a range of one to five or more weeks. Injections of methylprednisolone acetate have been well tolerated. Intrasynovial (intra-articular) injections may occasionally result in an increased localized inflammatory response.

Intrasynovial injection is recommended as an adjuvant to general therapeutic measures to effect suppression of inflammation in one or a few peripheral structures when (1) the disease is limited to one or a few peripheral structures; (2) the disease is widespread with one or a few peripheral structures actively inflamed; (3) systemic therapy with other corticoids or corticotropin controls all but a few of the more actively involved structures; (4) systemic therapy with cortisone, hydrocortisone, or corticotropin is contraindicated; (5) joints show early but actively progressing deformity (to enhance the effect of physiotherapy and corrective procedures); and (6) surgical or other orthopedic corrective measures are to be or have been done.

The action of DEPO-MEDROL Sterile Aqueous Suspension injected intrasynovially appears to be well localized since significant metabolic effects characteristic of systemic administration of adrenal steroids have not been observed. In a few instances mild and transient improvement of structures other than those injected have been reported. No other systemic effects have been noted. However, it is possible that mild systemic effects may occur following intrasynovial administration, and this possibility is greater the larger the number of structures injected and the higher the total dose employed.

Procedure for Intrasynovial Injection. The anatomy of the area to be injected should be reviewed in order to assure that the suspension is properly placed and to determine that large blood vessels or nerves are avoided. The injection site is located where the synovial cavity is most superficial. The area is prepared for aseptic injection of the medicament by the removal of hair and cleansing of the skin with alcohol or Mercresin® tincture. A sterile 18- to 21-gauge needle for horses, 20- to 22-gauge needle for dogs, on a dry syringe is quickly inserted into the synovial space and a small amount of synovial fluid withdrawn. If there is an excess of synovia and more than 1 mL of suspension is to be injected, it is well to aspirate a volume of fluid comparable to that which is to be injected. With the needle in place, the aspirating syringe is removed and replaced by a second syringe containing the proper amount of suspension which is then injected. In some animals a transient pain is elicited immediately upon injection into the affected cavity. This pain varies from mild to severe and may last for a few minutes up to 12 hours. After injection, the structure may be moved gently a few times to aid mixing of the synovial fluid and the suspension. The site may be covered with a small sterile dressing.

Areas not suitable for injection are those that are anatomically inaccessible such as spinal joints and those like the sacroiliac joints, which are devoid of synovial space. Treatment failures are most frequently the result of failure to enter the synovial space. If failures occur when injections into the synovial spaces are certain, as determined by aspiration of fluid, repeated injections are usually futile. Local therapy does not alter the underlying disease process, and whenever possible comprehensive therapy including physiotherapy and orthopedic correction should be employed.

The single intrasynovial dose depends on the size of the part, which corresponds to the size of the animal. The interval between repeated injections depends on the duration of relief obtained.

Horses. The average initial dose for a large synovial space in horses is 120 mg with a range from 40 to 240 mg. Smaller spaces will require a correspondingly lesser dose.

Dogs. The average initial dose for a large synovial space in dogs is 20 mg. Smaller spaces will require a correspondingly lesser dose.
Actogain

Actogain

Directions for Use (Complete Feed): Feed continuously to cattle fed in confinement for slaughter as the sole ration for the last 28 to 42 days on feed.

Directions for Use (Type C Medicated Top Dress Feed): Feed continuously to cattle fed in confinement for slaughter a Type C Medicated Feed containing up to a maximum of 800 g/ton ractopamine (see mixing direction table) to provide 70 to 400 mg per head per day for the last 28 to 42 days on feed. Type C Medicated Top Dress feed must be fed in a minimum of 1.0 lb per head per day to provide 70 to 400 mg per head per day.
Lutalyse Sterile

Lutalyse Sterile

As with any multi-dose vial, practice aseptic techniques in withdrawing each dose. Adequately clean and disinfect the vial stopper prior to entry with a sterile needle and syringe. No vial closure should be entered more than 20 times.

Cattle: LUTALYSE Sterile Solution is supplied at a concentration of 5 mg dinoprost per mL. LUTALYSE is luteolytic in cattle at 25 mg (5 mL) administered intramuscularly.

Swine: LUTALYSE Sterile Solution will induce parturition in swine at 10 mg (2 mL) when injected intramuscularly.

Mares:
1. Evaluate the reproductive status of the mare. 2. Administer a single intramuscular injection of 1 mg per 100 lbs (45.5 kg) body weight which is usually 1 mL to 2 mL LUTALYSE Sterile Solution. 3. Observe for signs of estrus by means of daily teasing with a stallion, and evaluate follicular changes on the ovary by palpation of the ovary per rectum. 4. Some clinically anestrous mares will not express estrus but will develop a follicle which will ovulate. These mares may become pregnant if inseminated at the appropriate time relative to rupture of the follicle. 5. Breed mares in estrus in a manner consistent with normal management.
Advocin

Advocin

ADVOCIN is administered subcutaneously at either 8 mg/kg of body weight (2 mL/100 lb) as a one time injection, or at 6 mg/kg of body weight (1.5 mL/100 lb) with this treatment repeated once approximately 48 hours following the first injection. Care should be taken to dose accurately. Administered dose volume should not exceed 15 mL per injection site.
ADVOCIN Dosage and Treatment Schedule Dose Volume (mL) Cattle Weight(lb) 6 mg/kg, given twice,48 hours apart 8 mg/kg given once * Administered dose volume should not exceed 15 mL per injection site. 50 0.75 1 100 1.5 2 150 2.25 3 200 3 4 250 3.75 5 300 4.5 6 400 6 8 500 7.5 10 600 9 12 700 10.5 14 800 12 16* 900 13.5 18* 1000 15 20*
Primor

Primor

DOSAGE AND ADMINISTRATION: Administer an initial oral dose of 25 mg/lb (55 mg/kg) of body weight on the first day of treatment. Administer subsequent daily doses at the rate of 12.5 mg/lb (27.5 mg/kg) of body weight. Continue treatment for at least 2 days after remission of clinical signs. Do not extend treatment for more than 21 consecutive days. Suggested dosage schedules follow:
Body Weight (lb)Up To No. of TabletsFirst Day No. of TabletsSubsequent Days Primor 120 5 1 1/2 10 2 1 15 3 1 1/2 Primor 240 10 1 1/2 20 2 1 30 3 1 1/2 Primor 600 25 1 1/2 50 2 1 Primor 1200 50 1 1/2 100 2 1
For optimal therapeutic effect: (1) the drug must be given early in the course of the disease; (2) therapeutically effective levels must be maintained in the body throughout the treatment period; (3) treatment should continue for at least 2 days after remission of clinical signs; and (4) the causative bacterial agents must be sensitive to the drug.
Terramycin Scours

Terramycin Scours

DOSAGE AND ADMINISTRATION: For control of bacterial enteritis and bacterial pneumonia orally administer 1 tablet per 100 lb of body weight every 12 hours (5 mg/ lb of body weight daily in divided doses) for up to 4 consecutive days.

For treatment of bacterial enteritis and bacterial pneumonia orally administer 2 tablets per 100 lb of body weight every 12 hours (10 mg/lb of body weight daily in divided doses) for up to 4 consecutive days.

Dosage should continue until the animal returns to normal and for 24–48 hours after symptoms have subsided. Treatment should not exceed 4 consecutive days.

Care of Sick Animals: The use of antibiotics in the management of disease is based on an accurate diagnosis and an adequate course of treatment. When properly used in the treatment of diseases caused by oxytetracycline-susceptible organisms, most animals treated with Terramycin Scours Tablets show a noticeable improvement within 24–48 hours. If improvement does not occur within this period of time, the diagnosis and course of treatment should be reevaluated. It is recommended that the diagnosis and treatment of animal diseases be carried out by a veterinarian. Since many diseases look alike but require different types of treatment, the use of professional veterinary and laboratory services can reduce treatment time, costs, and needless losses. Good housing, sanitation, and nutrition are important in the maintenance of healthy animals and are essential in the treatment of disease.

RECOMMENDED STORAGE: Store below 25°C (77°F).
Revolution

Revolution

DOSAGE:

The recommended minimum dose is 2.7 mg selamectin per pound (6 mg/kg) of body weight.

Administer the entire contents of a single dose tube (or two tubes used in combination for dogs weighing over 130 pounds) of Revolution topically in accordance with the following tables. (See ADMINISTRATION for the recommended treatment intervals.)
Cats (lb) Package color mg per tube Potency(mg/mL) Administered volume (mL) Up to 5 Mauve 15 mg 60 0.25 5.1–15 Blue 45 mg 60 0.75 15.1–22 Taupe 60 mg 60 1.0
For cats over 22 lbs use the appropriate combination of tubes.
Dogs (lb) Package color mg per tube Potency(mg/mL) Administered volume (mL) Up to 5 Mauve 15 mg 60 0.25 5.1–10 Purple 30 mg 120 0.25 10.1–20 Brown 60 mg 120 0.5 20.1–40 Red 120 mg 120 1.0 40.1–85 Teal 240 mg 120 2.0 85.1–130 Plum 360 mg 120 3.0
For dogs over 130 lbs use the appropriate combination of tubes.

Recommended for use in dogs 6 weeks of age and older and in cats 8 weeks of age and older.

ADMINISTRATION:

A veterinarian or veterinary technician should demonstrate or instruct the pet owner regarding the appropriate technique for applying Revolution topically to dogs and cats prior to first use.

Firmly press the cap down to puncture the seal on the Revolution tube; a clicking sound will confirm that the cap has successfully punctured the seal. Remove the cap and check to ensure that the tip of the tube is open. To administer the product, part the hair on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the tube on the skin and squeeze the tube 3 or 4 times to empty its entire contents directly onto the skin in one spot. Keeping the tube squeezed, drag it away from the liquid and lift to remove. Check the tube to ensure that it is empty. Do not massage the product into the skin. Due to alcohol content, do not apply to broken skin. Avoid contact between the product and fingers. Do not apply when the haircoat is wet. Bathing or shampooing the dog 2 or more hours after treatment will not reduce the effectiveness of Revolution against fleas or heartworm. Bathing or shampooing the cat 2 hours after treatment will not reduce the effectiveness of Revolution against fleas. Bathing or shampooing the cat 24 hours after treatment will not reduce the effectiveness of Revolution against heartworm. Stiff hair, clumping of hair, hair discoloration, or a slight powdery residue may be observed at the treatment site in some animals. These effects are temporary and do not affect the safety or effectiveness of the product. Discard empty tubes in your ordinary household refuse.

Flea Control in Dogs and Cats

For the prevention and control of flea infestations, Revolution should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. In controlled laboratory studies >98% of fleas were killed within 36 hours. Results of clinical field studies using Revolution monthly demonstrated >90% control of flea infestations within 30 days of the first dose. Dogs and cats treated with Revolution, including those with pre-existing flea allergy dermatitis, showed improvement in clinical signs associated with fleas as a direct result of eliminating the fleas from the animals and their environment.

If the dog or cat is already infested with fleas when the first dose of Revolution is administered, adult fleas on the animal are killed and no viable fleas hatch from eggs after the first administration. However, an environmental infestation of fleas may persist for a short time after beginning treatment with Revolution because of the emergence of adult fleas from pupae.

Heartworm Prevention in Dogs and Cats

For the prevention of heartworm disease, Revolution must be administered on a monthly basis. Revolution may be administered year-round or at least within one month after the animal's first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of Revolution and resumption of monthly dosing will minimize the opportunity for the development of adult heartworms. When replacing another heartworm preventive product in a heartworm disease prevention program, the first dose of Revolution must be given within a month of the last dose of the former medication.

Selamectin, the active ingredient in Revolution, is a macrocyclic lactone compound. These compounds effectively prevent the development of adult heartworms when administered to dogs and cats within one month of exposure to infective (L3) Dirofilaria immitis larvae. Efficacy of macrocyclic lactones decreases below 100% in dogs, however, if first administered >2 months after exposure to infective larvae. Thus, in heartworm endemic regions, delaying initiation of heartworm prevention using Revolution beyond 2 months of first exposure to infective larvae (e.g., starting puppies and kittens at >8 weeks of age), or gaps of >2 months in the administration of Revolution during periods of heartworm transmission, increases the risk of the animal acquiring heartworms. Animals with unknown heartworm history that test negative for heartworms prior to the initiation of Revolution may be harboring pre-patent infections at the time Revolution was started. Testing such animals 3–4 months after initiation of Revolution would be necessary to confirm their negative heartworm status.

At the discretion of the veterinarian, cats ≥6 months of age may be tested to determine the presence of existing heartworm infections before beginning treatment with Revolution. Cats already infected with adult heartworms can be given Revolution monthly to prevent further infections.

Ear Mite Treatment in Dogs and Cats

For the treatment of ear mite (O. cynotis) infestations in dogs and cats, Revolution should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of Revolution will control any subsequent ear mite infestations. In the clinical field trials ears were not cleaned, and many animals still had debris in their ears after the second dose. Cleansing of the infested ears is recommended to remove the debris.

Sarcoptic Mange Treatment in Dogs

For the treatment of sarcoptic mange (S. scabiei) in dogs, Revolution should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of Revolution will control any subsequent sarcoptic mange mite infestations. Because of the difficulty in finding sarcoptic mange mites on skin scrapings, effectiveness assessments also were based on resolution of clinical signs. Resolution of the pruritus associated with the mite infestations was observed in approximately 50% of the dogs 30 days after the first treatment and in approximately 90% of the dogs 30 days after the second monthly treatment.

Tick Control in Dogs

For the control of tick (Dermacentor variabilis) infestations in dogs, Revolution should be administered on a monthly basis. In heavy tick infestations, complete efficacy may not be achieved after the first dose. In these cases, one additional dose may be administered two weeks after the previous dose, with monthly dosing continued thereafter.

Nematode Treatment in Cats

For the treatment and control of intestinal hookworm (A. tubaeforme) and roundworm (T. cati) infections, Revolution should be applied once as a single topical dose.
Tritop

Tritop

In treatment of otitis externa and other inflammatory conditions of the external ear canal, a quantity of ointment sufficient to fill the external ear canal may be applied one to three times daily. When used on the skin or mucous membranes, cleanse the affected area, apply a small amount of the ointment and spread or rub in gently. The involved area may be treated one to three times a day and these daily applications continued in accordance with the clinical response. Limit treatment to the period when local anesthesia is essential to control self-inflicted trauma.
Excede Sterile

Excede Sterile

Treatment of BRD and bovine foot rot

Administer as a single subcutaneous injection in the posterior aspect of the ear where it attaches to the head (base of the ear) to cattle at a dosage of 3.0 mg ceftiofur equivalents (CE)/lb (6.6 mg CE/kg) body weight (BW) (1.5 mL sterile suspension per 100 lb BW).

In beef and non-lactating dairy cattle, EXCEDE Sterile Suspension may also be administered as a single subcutaneous injection in the middle third of the posterior aspect of the ear at a dosage of 3.0 mg CE/lb (6.6 mg CE/kg) BW (1.5 mL sterile suspension per 100 lb BW).

Most animals will respond to treatment within three to five days. If no improvement is observed, the diagnosis should be reevaluated.

Control of BRD

Administer as a subcutaneous injection either in the middle third of the posterior aspect of the ear or in the posterior aspect of the ear where it attaches to the head (base of the ear) to beef and non-lactating dairy cattle at a dosage of 3.0 mg CE/lb (6.6 mg CE/kg) BW (1.5 mL sterile suspension per 100 lb BW).

Clinical studies indicate that administration of EXCEDE Sterile Suspension is effective for the control of respiratory disease in beef and non-lactating dairy cattle at "high risk" of developing BRD. One or more of the following factors typically characterizes calves on arrival at high risk of developing BRD.
Cattle are from multiple farm origins, cattle have had extended transport times (that may have included few if any rest stops), ambient temperature change from origin to arrival of 30° F or more, cattle have had continued exposure to extremely wet or cold weather conditions, cattle have experienced excessive shrink or excessive arrival processing procedures (such as castration, dehorning).
Treatment of Acute Metritis

Administer as a subcutaneous injection in the posterior aspect of the ear where it attaches to the head (base of the ear) to lactating dairy cattle at a dosage of 3.0 mg CE/lb (6.6 mg CE/kg) BW (1.5 mL sterile suspension per 100 lb BW). Repeat this dose in the contra-lateral (opposite) ear approximately 72 hours following the initial dose.
Table 1. Dosing Schedule for EXCEDE Sterile Suspension. Weight(lb) Dose Volume(mL) Weight(lb) Dose Volume(mL) 100 1.5 1100 16.5 200 3.0 1200 18.0 300 4.5 1300 19.5 400 6.0 1400 21.0 500 7.5 1500 22.5 600 9.0 1600 24.0 700 10.5 1700 25.5 800 12.0 1800 27.0 900 13.5 1900 28.5 1000 15.0 2000 30.0
ADMINISTRATION FOR THE MIDDLE THIRD OF THE EAR
Shake well before using. Please read the complete package insert before administering EXCEDE Sterile Suspension subcutaneously in the posterior ear of cattle. Deposit as a single subcutaneous injection in the middle third of the posterior aspect of the ear, avoiding all blood vessels. See Figures 2 and 3. Adjust the needle insertion point to avoid any blood vessels, previous implants, ear tags or ear tag holes. Do not administer intra-arterially. Deliver the entire contents of the syringe. When administered correctly, a subcutaneous bleb of EXCEDE Sterile Suspension will appear. When withdrawing the needle, apply pressure to the needle insertion point, and massage toward the base of the ear.
Figure 2. Subcutaneous administration of EXCEDE Sterile Suspension in the middle third of the posterior aspect of the ear.

Figure 3. Diagram of the approximate locations of the major arteries of the posterior ear and the recommended needle insertion locations. Administration of EXCEDE Sterile Suspension into ear arteries is likely to be fatal.

In lactating dairy cattle the injection techniques for subcutaneous (SC) injection in the posterior aspect of the ear where it attaches to the head (base of the ear) can be made by the rostral or ventral injection techniques.

In beef and non-lactating dairy cattle the SC injection in the base of the ear can be made by the rostral, ventral or toward the opposite eye injection techniques.
Shake well before using. Please read the complete package insert before administering EXCEDE Sterile Suspension subcutaneously in the posterior aspect of the ear where it attaches to the head (base of the ear). The subcutaneous (SC) injection may be made using the toward the opposite eye, rostral, or ventral techniques. Hold the syringe and needle and insert the needle as described below. Deliver the entire contents of the syringe. Do not administer EXCEDE Sterile Suspension in the neck.
Administration for the Base of the Ear: Toward the Opposite Eye Technique
Hold the syringe and needle behind the ear to be dosed so the needle and syringe point in the direction of an imaginary line that would pass through the head toward the animal's opposite eye. See Figures 4 and 5. Insert the needle through the loose skin in the posterior aspect of the ear where it attaches to the head (base of the ear) while maintaining this angle. See Figure 4.
Figure 4. Subcutaneous administration of EXCEDE Sterile Suspension in the posterior aspect of the ear where it attaches to the head (base of the ear).

Figure 5. Injection location for the subcutaneous administration of EXCEDE Sterile Suspension in the posterior aspect of the ear where it attaches to the head (base of the ear).

Administration for the Base of Ear: Toward the Same Eye Technique or Rostral Direction
Hold the syringe and needle behind the ear to be dosed so the needle and syringe point in the direction of an imaginary line that would pass through the head toward the eye on the same side of the head. See Figures 5 and 6. Insert the needle through the loose skin in the posterior aspect of the ear where it attaches to the head (base of the ear) while maintaining the needle position. See Figure 6.
Figure 6. Diagram of head showing the direction for the base of ear injections administered rostrally toward the eye on the same side of the head into the loose skin in the caudal aspect of the base of the ear.

Administration for Base of the Ear: Ventral Technique
Hold the syringe and needle above the ear to be dosed so that the needle and syringe are pointing ventrally toward the base of the ear. The needle will be inserted into the loose skin in the posterior aspect of the ear where it attaches to the head (base of the ear) while pointing ventrally. Care should be taken to not insert the needle through the cartilage of the ear. See Figure 7. Insert the needle through the loose skin in the posterior aspect of the ear where it attaches to the head (base of the ear) while maintaining needle position. See Figure 7.
Figure 7. Diagram of head showing the direction of base of ear injections when administered ventrally into the loose skin in the caudal aspect of the base of the ear.

Shake well before using.

Administer two intramuscular injections to horses, 4 days apart, at a dose of 3.0 mg/lb (6.6 mg/kg). A maximum of 20 mL per injection site may be administered. Therapeutic drug concentrations are maintained for 6 days after the second injection (or a total of 10 days from the beginning of treatment) against Streptococcus equi ssp. zooepidemicus.
Table 1. Dosing Schedule for EXCEDE Sterile Suspension. Weight(lb) Dose Volume(mL) Weight(lb) Dose Volume(mL) 100 1.5 1100 16.5 200 3.0 1200 18.0 300 4.5 1300 19.5 400 6.0 1400 21.0 500 7.5 1500 22.5 600 9.0 1600 24.0 700 10.5 1700 25.5 800 12.0 1800 27.0 900 13.5 1900 28.5 1000 15.0 2000 30.0
Strongid T

Strongid T

DOSAGE AND ADMINISTRATION: Administer 3 mg pyrantel base per lb of body weight (6 mL Strongid T per 100 lb of body weight). For maximum control of parasitism, it is recommended that foals (2–8 months of age) be dosed every 4 weeks. To minimize potential hazard that the mare may pose to the foal, she should be treated 1 month prior to anticipated foaling date followed by retreatment 10 days to 2 weeks after birth of foal. Horses over 8 months of age should be routinely dosed every 6 weeks.

Directions for use: Strongid T may be administered by means of a stomach tube, dose syringe or by mixing into the feed.

Stomach Tube: Measure the appropriate dosage of Strongid T and mix in the desired quantity of water. Protect drench from direct sunlight and administer to the animal immediately following mixing. Do not attempt to store diluted suspension. Strongid T is inactive against the common horse bot (Gasterophilus spp.) However, Strongid T may be administered concurrently with carbon disulfide observing the usual precautions with carbon disulfide.

Dose Syringe: Draw the appropriate dosage of Strongid T into a dose syringe and administer to the animal. Do not expose Strongid T to direct sunlight.

Feed: Mix the appropriate dosage of Strongid T in the normal grain ration. Fasting of animals prior to or following treatment is not required.
Improvest

Improvest

DOSAGE AND ADMINISTRATION: IMPROVEST should be administered via subcutaneous injection into the post auricular region of the neck. A safety injector should be used, preferably one which has a dual safety system providing both a needle guard and a mechanism to prevent accidental operation of the trigger. Each intact male pig should receive two 2-mL doses of IMPROVEST. The first dose should be administered no earlier than 9 weeks of age. The second dose should be administered at least 4 weeks after the first dose. Pigs should be slaughtered no earlier than 3 weeks and no later than 10 weeks after the second dose. In case of misdosing, the animal should be re-dosed immediately.

Zoetis Inc.

Manufacturer Details

Share This Page

Zoetis Inc. Drugs